

I. Remarks

Sequence Listing:

In compliance with 37 C.F.R. § 1.821, Applicants have enclosed a Sequence Listing for the instant specification. This Sequence Listing conforms to the requirements of 37 C.F.R. 1.821-1.824. It comprises a paper copy of the Sequence Listing in accordance with 37 C.F.R. § 1.821(c) and a computer readable form of the Sequence Listing in the form of a compact disk in accordance with 37 C.F.R. § 1.821(e).

Applicants hereby submit the statement required under 37 C.F.R. § 1.821(f) that the sequence listing information recorded in computer readable form (compact disk) is identical to the written (paper copy) of the sequence listing. Applicants also submit the statement required under 37 C.F.R. § 1.821(g) that the sequence listing information provided in the paper copy and that provided in computer readable form contains no new matter.

Amendment to the Specification:

Applicants respectfully request that the instant specification be amended to enter the enclosed Sequence Listing therein.

II. Conclusion

No fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

March 9, 2004
Date

Respectfully submitted,



Jennifer D. Tousignant
Agent for Applicants
Registration No. 54,498
Telephone: (508) 270-2499
Facsimile: (508) 872-5415

GENZYME CORPORATION
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322